New Insights into Radiopharmaceuticals for Cancer Therapy and Diagnosis
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 March 2027 | Viewed by 41
Editors
Interests: radiochemistry; radiopharmacy; quality control development; preclinical studies; education in radiopharmacy
2. Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
Interests: radiochemistry; production of radionuclides; targeted radionuclide therapy; alpha emitters; Auger emitters
Interests: nanotechnology; radiopharmacy; biomaterials; nuclear medicine; nuclear technology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Radiopharmaceuticals have emerged as a central pillar of precision oncology, offering unique opportunities for the noninvasive interrogation of molecular pathways and the selective treatment of malignancies. Advances in radiochemistry, molecular imaging, radionuclide production, and targeted delivery systems have markedly broadened the diagnostic and therapeutic scope of these agents. In parallel, the development of new targeting vectors, including peptides, antibodies, proteins, nanoparticles, and small molecules, together with theranostic strategies, has accelerated the transition toward more individualized oncologic care, with the dual aim of enhancing efficacy and reducing off-target toxicity.
This Special Issue is intended to showcase the latest advances in radiopharmaceutical research for cancer diagnosis and therapy across fundamental, translational, and clinical domains. Contributions are invited that address the design and optimization of novel radiopharmaceuticals; emerging radionuclides and innovations in radiochemical methodology; theranostic approaches and personalized medicine; targeting strategies based on peptides, antibodies, proteins, nanoparticles, and small molecules; radiopharmaceutical delivery systems and nanomedicine; PET, SPECT, and hybrid imaging technologies; dosimetry, pharmacokinetics, and biodistribution; preclinical evaluation and translational development; clinical applications and trials; artificial intelligence and computational tools in radiopharmaceutical innovation; and safety, toxicity, regulatory considerations, and future directions in nuclear medicine.
Dr. Fabio Luiz Navarro Marques
Dr. Valery I. Radchenko
Dr. Aryel Heitor Ferreira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- precision oncology
- cancer imaging
- targeted radionuclide therapy
- theranostics
- molecular imaging
- radiochemistry
- PET/SPECT
- nuclear medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
